IMV, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorHealth Technology
CIKN/A
WebN/A
Phone(902) 492-1819
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/22/2019 (Confirmed)
OptionableNot Optionable
IMV (NYSE:IMV) Frequently Asked Questions
What is IMV's stock symbol?
IMV trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMV."
When is IMV's next earnings date?
What price target have analysts set for IMV?
2 brokers have issued 12 month price targets for IMV's shares. Their predictions range from $10.00 to $10.00. On average, they anticipate IMV's stock price to reach $10.00 in the next year. This suggests a possible upside of 140.4% from the stock's current price. View Analyst Price Targets for IMV.
What is the consensus analysts' recommendation for IMV?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMV.
Has IMV been receiving favorable news coverage?
News coverage about IMV stock has trended somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IMV earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of IMV's key competitors?
Some companies that are related to IMV include Mesoblast (MSB), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Theratechnologies (TH), Biotest (BIO), Polynovo (PNV), Oxford BioMedica (OXB), Senesco Technologies (ELOX), Starpharma (SPL), Neptune Wellness Solutions (NEPT), Enochian Biosciences (ENOB), Monash IVF Group (MVF), Kodiak Sciences (KOD), Horizon Discovery Group (HZD) and Emblem (EMC).
What other stocks do shareholders of IMV own?
Who are IMV's key executives?
IMV's management team includes the folowing people:
- Frederic Ors, CEO, Director & Chief Business Officer
- Pierre Labbé, Chief Financial Officer
- Gabriela Nicola Rosu, Chief Medical Officer
- Marianne Stanford, Vice President-Research
- Joseph Sullivan, Senior Vice President-Business Development
Who are IMV's major shareholders?
IMV's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Ruffer LLP (13.63%), Hartford Financial Management Inc. (0.06%), Prentiss Smith & Co. Inc. (0.05%) and Ipswich Investment Management Co. Inc. (0.01%).
Which institutional investors are selling IMV stock?
IMV stock was sold by a variety of institutional investors in the last quarter, including Prentiss Smith & Co. Inc..
Which institutional investors are buying IMV stock?
IMV stock was purchased by a variety of institutional investors in the last quarter, including Ruffer LLP, Ipswich Investment Management Co. Inc. and Hartford Financial Management Inc..
How do I buy shares of IMV?
Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IMV's stock price today?
One share of IMV stock can currently be purchased for approximately $4.16.
How big of a company is IMV?
IMV has a market capitalization of $210.47 million.
How can I contact IMV?
The company can be reached via phone at (902) 492-1819.
MarketBeat Community Rating for IMV (NYSE IMV)
MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
